Patrick O'Keefe, Ph.D.
GSTs in the Framework of Structural Equation Models: Type I error and power
Caleb Dayley, M.S.
Why Placebo Progression Should Be the Gold Standard for Endpoint Validation in Clinical Trials for Progressive Diseases
John Whetten, M.S.
Estimating Time Savings for Individual Participants in Clinical Trials for Progressive Diseases
Daniel Smith, M.S.
Comparing Parametric and Non-Parametric Time Saving Estimates in Clinical Trials